CD274 (B7-H1) Antibody, anti-human, REAfinity™
Synonyms: programmed cell death 1 ligand 1, PD-L1, PDCD1L1, PDCD1LG1, PDCD1 ligand 1, B7 homolog 1, B7H1
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
14 Citations5 Images
Clone:
REA1197 | MIH1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, 3D-IF, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD274 (B7-H1) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 615
PE-Vio 670
PE-Vio 770
Vio B515
Vio Bright B515
Vio Bright R720
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-122-810, 130-122-816
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left peak) or stimulated with 5 µg/mL PHA for 48 hours. Cells were then stained with CD274 (B7-H1) antibodies as well as with CD3 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
3D-Immunofluorescence applications
Vio R667
Tissue clearing:
MACS® Clearing Kit
Fixation:
PFA
Species tested:
human
Tissue used:
colorectal cancer
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
Vio R667
Used products:
130-131-637
Description:
3D-immunofluorescence analysis of human colorectal cancer fixed with 4% PFA and subjected to whole-mount immunostaining with PD-L1 Antibody, anti human, Vio® R667 (red). The sample was processed and optically cleared using the MACS® Clearing Kit and imaged with an UltraMicroscope Blaze light sheet instrument. Sample detail image (A), overview image (B), maximum intensity projection (C) and 3D-rendered video. Autofluorescence is visualized in grey. Scale bars: 500 µm (A), 200 µm (B).

A

Application imageView details view details

B

Application imageView details view details

C

Application imageView details view details
Extended validation for CD274 (B7-H1) Antibody, anti-human, REAfinity™
Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD274 (B7-H1). Monocyte derived dendritic cells (MODCs) were stained with CD274 (B7-H1) antibodies and with a suitable counterstaining. As a control, CD274 (B7-H1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD274 (B7-H1) (REA1197). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD274 (B7-H1) Antibody, anti-human, REAfinity™
Overview

Clone REA1197 recognizes the human CD274 antigen, also known as programmed cell death 1 ligand 1 (PD-L1), an immune inhibitory receptor ligand which is involved in the costimulatory signal, essential for T cell proliferation and production of interleukin 10 (IL-10) and interferon γ (IFN-γ).

CD274 is expressed on activated T cells, B cells, dendritic cells (DCs), antigen-presenting cells, keratinocytes, monocytes, and various types of tumor cells. In tissues, CD274 is highly expressed in the heart, skeletal muscle, placenta, and lung and weakly expressed in the thymus, spleen, kidney, and liver.

PD-L1 is a type I transmembrane protein that has immunoglobulin V-like and C-like domains.

Additional information: Clone REA1197 displays negligible binding to Fc receptors.

Alternative names

programmed cell death 1 ligand 1, PD-L1, PDCD1L1, PDCD1LG1, PDCD1 ligand 1, B7 homolog 1, B7H1

Detailed product information

Technical specifications

Clone
REA1197
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD274 (B7-H1)
Molecular mass of antigen [kDa]
31
Distribution of antigen
antigen-presenting cells, B cells, dendritic cells, keratinocytes, monocytes, T cells, tumor cells, thymocytes
Entrez Gene ID
RRID
AB_2811403, AB_2811397, AB_2811392, AB_2811402, AB_2811394, AB_2811400, AB_2811395, AB_2811396, AB_2811399, AB_2811398, AB_2811401, AB_2811393

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD274 (B7-H1) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support